About this trial
Lung cancer is the leading cause of cancer related death worldwide. Lobectomy or sub-lobectomy with mediastinal lymph node dissection is the standard surgery. About 50% lung nodules are pure ground-glass or part-solid nodules. Non-solid nodules rarely develop mediastinal lymph node metastasis. The present study is a prospective, multicenter and randomized clinical trial, comparing the overall survival and disease-free survival of whether performing mediastinal lymph node dissection in non-small cell lung cancer with ground-glass nodule CT features.
Eligibility criteria
Qualifiers
Thin-slice HRCT shows single GGN with C/T ≤ 0.5 and no lymph node metastasis;
Clinical stage IA NSCLC (TNM 8th classification) diagnosed prior or in surgery;
No history of malignancies within past 5 years or lung surgery;
No anti-cancer treatment prior to surgery.
Disqualifiers
Simultaneous or metachronous (within the past 5 years) double cancers;
Active bacterial or fungous infection;
Interstitial pneumonitis, pulmonary fibrosis, or severe pulmonary emphysema;
Systemic steroidal medication;
Trial design
Treatments tested in this trial
- Systemic mediastinal lymph node dissection
- Spared mediastinal lymph node dissection